
09/24/2025
📉 Shares of Charles River Laboratories (NYSE: CRL) are down 14% this year, and hedge funds are divided.
Upslope Capital bailed after the FDA announced the phase-out of animal testing for certain drugs. Meanwhile, Oakmark and others see a buy-the-dip opportunity, citing the company’s moat and long-term growth potential.
Will CRL rebound or stay in the doldrums? Full story 👉 https://hedgefundalpha.com/stock-analysis/hedge-funds-split-charles-river-laboratories/
Hedge funds are split on Charles River Laboratories (CRL): Oakmark buys the dip while Upslope exits after an FDA policy shift on testing.